HAEMONETICS CORP (HAE)
HAEMONETICS CORP (HAE) from its SEC filings: 2025 revenue $1.3 billion (-2% vs the year before), net margin 0%, free cash flow $260.4 million. Insider trades, recent filings and a price chart. Free.
| Exchange | NYSE |
| Industry | Surgical & Medical Instruments & Apparatus |
| Revenue (2025) | $1.3 billion |
| Revenue growth | -2% |
| Net income | $97,308 |
| Net margin | 0.0% |
| Free cash flow | $260.4 million |
| Diluted EPS | $2.05 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +6% |
| Cash | $223.4 million |
| Long-term debt | $1.2 billion |
| Share count, 1 year | -6% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-24. Education only, not financial advice.